Viewing Study NCT00101595


Ignite Creation Date: 2025-12-24 @ 1:58 PM
Ignite Modification Date: 2026-07-09 @ 1:35 PM
Study NCT ID: NCT00101595
Status: COMPLETED
Last Update Posted: 2011-04-14
First Post: 2005-01-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Sponsor: Bristol-Myers Squibb
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module